ABT-761: Discontinued

GENXY and Abbott scientists published in Nature Genetics a retrospective pharmacogenetic analysis of 221 patients treated in two clinical trials of ABT-761, a second generation version of Abbott's Zyflo zileuton 5-lipoxygenase inhibitor, showing that patients who carried two mutant copies of ALOX5, the gene encoding 5-lipoxygenase, did not respond to treatment. Of patients receiving ABT-761, those with wild-type or heterozygous genotype had a significantly greater increase in forced expiratory volume (FEV) than those with a mutant genotype that results in reduced expression of the target enzyme (p<0.0001 and p=0.0006, respectively).

The researchers suggested that other patients who fail to respond to 5-lipoxygenase inhibitors may have other underlying causes for their airway obstruction besides leukotriene production. ...